Xvivo Perfusion AB, a leading healthcare company based in Sweden, specializes in medical technology that prolongs the life of organs for transplantation, enhancing the success rate of life-saving procedures worldwide. The company operates in three key segments - Thoracic, Abdominal, and Services, focusing on lung, heart, liver, and kidney transplant products. With a low-risk ESG score of 19.8, Xvivo Perfusion AB is dedicated to sustainability and governance practices. Its innovative solutions empower clinicians and researchers to advance the field of transplantation medicine, primarily serving the United States market.